title: ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent.
abstract: Radiation therapy plays a potential curative role in the treatment of patients with non-small-cell lung cancer with locoregional disease who are not surgical candidates and a palliative role for patients with metastatic disease. Stereotactic body radiation therapy is a relatively new technique in patients with early-stage non-small-cell lung cancer. A trial from RTOG(®) reported >97% local control at 3 years. For patients with locally advanced disease, thoracic radiation to a dose of 60 Gy remains the standard of care. Sequential chemotherapy or radiation alone can be used for patients with poor performance status who cannot tolerate more aggressive approaches. Chemotherapy should be used for patients with metastatic disease. Radiation therapy is useful for palliation of symptomatic tumors, and a dose of approximately 30 Gy is commonly used. Endobronchial brachytherapy is useful for patients with symptomatic endobronchial tumors. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
authors.affiliation: Mount Sinai School of Medicine, New York, NY, USA. kenneth.rosenzweig@mountsinai.org
authors.forename: Kenneth E
authors.initials: KE
authors.lastname: Rosenzweig
authors.forename: Joe Yujiao
authors.initials: JY
authors.lastname: Chang
authors.forename: Indrin J
authors.initials: IJ
authors.lastname: Chetty
authors.forename: Roy H
authors.initials: RH
authors.lastname: Decker
authors.forename: Mark E
authors.initials: ME
authors.lastname: Ginsburg
authors.forename: Larry L
authors.initials: LL
authors.lastname: Kestin
authors.forename: Feng-Ming Spring
authors.initials: FM
authors.lastname: Kong
authors.forename: Brian E
authors.initials: BE
authors.lastname: Lally
authors.forename: Corey J
authors.initials: CJ
authors.lastname: Langer
authors.forename: Benjamin
authors.initials: B
authors.lastname: Movsas
authors.forename: Gregory M M
authors.initials: GM
authors.lastname: Videtic
authors.forename: Henning
authors.initials: H
authors.lastname: Willers
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D059248:Chemoradiotherapy / Q000592:standards*; D019317:Evidence-Based Medicine; D019983:Guideline Adherence; D017408:Guidelines as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D008495:Medical Oncology / Q000592:standards*; D011878:Radiotherapy / Q000592:standards*; D014481:United States
keywords: Appropriateness criteria; non–small-cell lung cancer; palliation; radiation therapy